Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) slow down progression of cardiovascular diseases and reduce risk of mortality and life threatening complications. What it is better to prescribe for patient in a concrete clinical case – ACE inhibitors or ARB? Authors compare these drug classes (mechanism of action, indications, evidense base of clinical trails, treatment costs and safety). The place of ACE inhibitors and ARB in modern therapy of cardiovascular diseases is defined. Results of the recent trails (ONTARGET, TRANCEND, PRoFESS, I-PRESERVE) are discussed.

About the Authors

L. N. Malay
Hospital of Federal Security Service of Russia in Khabarovsk Territory
Russian Federation
Polyarnaya ul. 1, Khabarovsk, 680018

A. N. Miroshnichenko
Hospital of Federal Security Service of Russia in Khabarovsk Territory
Russian Federation
Polyarnaya ul. 1, Khabarovsk, 680018

B. V. Sharykin
Hospital of Federal Security Service of Russia in Khabarovsk Territory
Russian Federation
Polyarnaya ul. 1, Khabarovsk, 680018

V. V. Konurovsky
Hospital of Federal Security Service of Russia in Khabarovsk Territory
Russian Federation
Polyarnaya ul. 1, Khabarovsk, 680018


1. Davis J.O. The second Volhard Lecture: The use of blocking agents to de￾fine the functions of the renin--angiotensin system. Clin Sci Mol Med Suppl 1975;2:3s-14s.

2. Gavras H., Brunner H.R., Turini G.A., et al. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med. 1978;298(18):991-5.

3. Dzau V.J., Antman E.M., Black H.R. et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006;114(25):2850-70.

4. Преображенский Д.В., Патарая С.А. Кандесартан — блокатор АТ1- ангиотензиновых рецепторов длительного действия: особенности фармакологии и опыт клинического применения. Consilium medicum 2006;8(11):3-10.

5. Скворцов А.А., Мареев В.Ю., Беленков Ю.Н. Место блокаторов рецепторов ангиотензина II в лечении больных ХСН. Сердце 2008;5:275-83.

6. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. М.: ГЭОТАР- Медиа; 2006.

7. Horiuchi M., Akishita M., Dzau V.J. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33(2):613-21.

8. Akishita M., Yamada H., Dzau V.J., Horiuchi M. Increased vasoconstrictor response of the mouse lacking angiotensin II type 2 receptor. Biochem Biophys Res Commun 1999;261(2):345-9.

9. Кобалава Ж.Д., Шаварова Е.К. Место антагонистов рецепторов к ангиотензину II в современных рекомендациях. Сердце 2008;5:270-4.

10. Беленков Ю.Н.. Оганов Р.Г., редакторы. Кардиология. Национальное руководство. М.:ГЭОТАР-Медиа; 2007.

11. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325(5):293-302.

12. Yusuf S., Pfreffer M., Swedberg K. et al. CHARM Investigatorsand Committeees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362(9386):777-81.

13. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute In￾farction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-8.

14. Hall A.S., Murray G.D., Ball S.G. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 1997;349(9064):1493-97.

15. Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensinconverting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332(2):80-5.

16. Zuanetti G., Latini R., Maggioni A.P. et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997;96(12): 4239-45.

17. Pfeffer M.A., Braunwald E., Moy L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327(10): 669-77.

18. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355(9200):253-9.

19. Fox K.M.; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).Lancet 2003; 362(9386): 782-8.

20. Braunwald E., Domanski M.J., Fowler S.E. et al.; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable corona￾ry artery disease. N Engl J Med 2004;351(10):2058-68.

21. Yusuf S., Teo K.K., Pogue J. et al.; ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N Engl J Med 2008;358(15):1547-59.

22. Карпов Ю.А. Ингибиторы ангиотензинпревращающего фермента и лечение стабильной ишемической болезни сердца: послесловие к рекомендациям Европейского общества кардиологов. Кардиология 2007;(9):34-40.

23. Чазова И.Е., Ратова Л.Г. Современные клинические рекомендации по артериальной гипертонии. Сердце 2008; 3(41): 136-138.

24. Teo K.K., Mitchell L.B., Pogue J. et al.; HOPE Investigators. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in highrisk individuals without heart failure or left ventricular dysfunction. Circulation 2004;110(11):1413-7.

25. Преображенский Д.В., Батыралиев Т.А., Пересыпко М.К. Антиатерогенные эффекты ингибиторов ангиотензинпревращающего фермента с точки зрения доказательной медицины. Часть II. Кар- диология 2007;(5):73-86.

26. Перепеч Н.Б. Нефропротекция у больных с артериальной гипертензией: выбор средств защиты. Сердце 2008;3:157-63.

27. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997;349(9068): 1787-92.

28. Agardh C.D., Garcia-Puig J., Charbonnel B. et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996;10(3):185-92.

29. DREAM Trial Investigators, Bosch J., Yusuf S., Gerstein H.C. et al. The DREAM Trial Investigators. Effects of Ramipril on the Incidence of Diabetes. N Engl J Med 2006;355(15):1551-62.

30. Глезер М.Г. Антигипертензивная терапия и сахарный диабет. Проблемы женского здоровья 2007; 3 (2):45-67.

31. Lindholm L.H., Ibsen H., Dahl￾f B. et al.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359(9311):1004-10.

32. Schrader J., Lders S., Kulschewski A. et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36(2):1218-1226.

33. Lithell H., Hansson L., Skoog I. et all. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized doubleblind intervention trial. J Hypertens 2003;21(5):875-886.

34. Reboldi G., Angeli F., Cavallini C. et al. Comparison between angiotensinconverting enzyme inhibitors and angiotensin receptors blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008; 26(7): 1282-9.

35. Yusuf S., Diener H.C., Sacco R.L. et al. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. N Engl J Med 2008;359(12): 1225-1237.

36. Лопатин Ю.М. Комбинированная блокада ренин-ангиотензинальдостероновой системы: сочетание ингибитора АПФ и блокаторов рецепторов ангиотензина II. Сердце 2008;5:256-60.

37. Pitt B., Segal R., Martinez F.A. et all. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349 (9054):747-52.

38. Pitt B., Poole-Wilson P.A., Segal R. et al. Effect of losartan compared with catopril on mortality in patients with symptomatic heart failure; randomized trial – the Losartan Heart Failure Survial Study ELITE II. Lancet 2000;355(9215):1582-7.

39. Розанов А.В. От факторов риска к сердечной недостаточности. Возможности применения антагонистов рецепторов ангиотензина II для замедления прогрессирования сердечно-сосудистых заболеваний. Проблемы женского здоровья 2007;4(2):61-70.

40. Pfeffer M.A., Swedberg K., Granger C.B. et al. CHARM Investigators and Commitees. Effects of candersartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362(9386):759-66.

41. McMurray J., Ostergren J., Pfeffer M. et al. CHARM committees and investigators. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure; baseline characteristics of patients in the Candersartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003;5(3):261-70.

42. Massie B.M., Carson P.E., McMurrey J.J. et al. Irbersartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359(23):2456-67.

43. Cohn J.N., Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345(23):1667-75.

44. Parving H.H., Lehnert H., Brchner-Mortensen J. et al. The effects of irbesartan on the development of diabetic nephropathy in patients with types 2 diabetes. N Engl J Med 2001;345(12):870-8. (IRMA).

45. Lewis E.J., Hunsisker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12): 851-60.

46. Brenner B.M., Cooper M.E., de Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12): 861-9.

47. Viberti G., Wheeldon N.M. MicroAlbumininuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbumininuria reduction with valsartan in patients with type II diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106(6):672-8.

48. Lindholm L.H., Persson M., Alaupovic P. et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003;21(8):1563-74.

49. Julius S., Kjeldsen S.E., Weber M. et al. Outcome in hypertensive patients at high cardoivascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004;363(9426):2022-31.

50. Teo K., Yusuf S., Sleight P. et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/ Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart 2004;148(1):52-61.

51. Pfeffer M., McMurray J., Velasquez E. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, ventricular dysfunction, or both. N Engl J Med 2003; 349(20): 1893-1906.

52. Phillips C.O., Kashani A., Ko D.K. et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007;167(18): 1930-1936.

53. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008; 372(9644): 1174-83.

54. Бойцов С.А., Колос И.П. К вопросу о месте блокаторов рецепторов ангиотензина II в лечении артериальной гипертензии. Рациональная Фармакотерапия в Кардиологии 2008;(4): 69-75.

55. Mancia G., Backer G., Dominiczak A. et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007;25(9):1751-1762.

For citation:

Malay L.N., Miroshnichenko A.N., Sharykin B.V., Konurovsky V.V. TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS. Rational Pharmacotherapy in Cardiology. 2009;5(4):85-92. (In Russ.)

Views: 315

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)